A clinical study indicates that a new treatment for psoriasis could be linked to a significant decrease in vascular inflammation. The study was co-led by the Canada-based Montreal Heart Institute and Innovaderm Research Inc.
The results suggest a 51% decrease in C-reactive protein among patients treated with adalimumab, compared to a 2% decrease exhibited by patients in the control group. These findings are significant, researchers say, in relation to the association between high levels of C-reactive protein and an increased risk of stroke and heart attack. The study also indicates that during psoriasis treatment, 70% of patients who received adalimumab exhibited major decreases in skin lesion severity, compared to 20% of patients in the control group.
Jean Claude Tardif, MD, director of the Research Center of the Montreal Heart Institute, co-principal study author, notes that the study’s findings are, “encouraging for patients suffering from psoriasis, as they face a greater risk of cardiovascular.”
Source(s): Montreal Heart Institute, Innovaderm Research Inc,